Research programme: cognition disorder therapeutics - Cortice Biosciences
Alternative Names: B1-ADR partial agonist- Cortice Biosciences; CRT 001; Xalmoterol fumarate - Cortice BiosciencesLatest Information Update: 28 Aug 2018
At a glance
- Originator Stanford University
- Developer Cortice Biosciences
- Class Small molecules
- Mechanism of Action Beta 1 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Cognition disorders; Down syndrome
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 28 Aug 2018 No recent reports of development identified for preclinical development in Cognition-disorders in USA
- 28 Aug 2018 No recent reports of development identified for preclinical development in Down syndrome in USA